What Is Geographic Atrophy?

​

Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that affects the macula, the central part of the retina responsible for detailed vision.

 

In GA, retinal cells gradually break down over time, leading to permanent areas of damage within the macula. As these areas enlarge, patients may experience increasing difficulty with activities such as reading, driving, recognizing faces, and seeing fine detail.

 

Unlike Wet AMD, geographic atrophy does not involve abnormal leaking blood vessels, but vision loss may still progress over time.

​

Common Symptoms

​

Symptoms of geographic atrophy may include:

​

• Blurred or missing areas in central vision

• Difficulty reading or seeing fine details

• Trouble recognizing faces

• Increased need for brighter lighting

• Slower adjustment between light and dark environments

• Reduced contrast sensitivity

 

Symptoms often develop gradually and may worsen as the affected areas expand.

​

Why Clinical Trials Matter

​

Clinical trials for geographic atrophy are helping researchers study new therapies aimed at slowing disease progression and preserving vision.

 

Research studies may evaluate investigational medications, imaging technologies, or emerging treatment approaches designed to better understand and manage retinal disease. Participation in clinical research contributes to ongoing efforts to improve future treatment options for patients living with GA.

​

Each clinical trial has specific eligibility requirements, and participation is always voluntary.